Enovis (NYSE:ENOV) Stock: Insider Sharon Wienbar Buys 907 Shares

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar acquired 907 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was purchased at an average cost of $27.55 per share, with a total value of $24,987.85. Following the transaction, the director owned 42,853 shares in the company, valued at approximately $1,180,600.15. This trade represents a 2.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Enovis Stock Up 1.4%

Enovis stock opened at $28.62 on Thursday. The firm has a market capitalization of $1.65 billion, a PE ratio of -3.11 and a beta of 1.31. The company’s 50-day moving average is $20.21 and its 200-day moving average is $23.16. Enovis Corporation has a fifty-two week low of $16.70 and a fifty-two week high of $32.41. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same period last year, the business posted $0.75 EPS. Enovis’s revenue was up 1.8% on a year-over-year basis. Sell-side analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. BTIG Research raised their price objective on Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Citizens Jmp decreased their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. Wells Fargo & Company boosted their target price on Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, BMO Capital Markets set a $27.00 price target on Enovis in a report on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY lifted its position in Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. Private Management Group Inc. grew its position in shares of Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after purchasing an additional 427,347 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after purchasing an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. increased its stake in shares of Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after purchasing an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP increased its stake in shares of Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after purchasing an additional 342,556 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.